glp 2tz tirzepatide GLP-2 TZ (Tirzepatide) | Dual Agonist (GIP/GLP-1) GLP-2TZ – Performance Peptides

The longer duration (68 weeks vs 48 weeks in Phase 2) allowed assessment of sustained efficacy

In practical terms, clinical trial data has shown patients on the highest tirzepatide dose losing close to 21% of their body weight, compared to roughly 15% for patients on the highest semaglutide dose

A similar rationale underpins regimens for Friedreichs ataxia, where riboflavin plus antioxidants (CoQ10, -lipoic acid) counter mitochondrial ironsulfur-cluster loss and free-radical injury, offering symptom relief beyond monotherapy (79, 80)

Glutathione and its antiaging and antimelanogenic effects, PubMed

Because these factors can be complex, patients should not start tirzepatide without medical evaluation